TITLE:
A model System for Validation of PET Radiopharmaceuticals: Focusing on Tumor Microenvironment
AUTHORS:
Xiao-Feng Li, Huijie Jiang, Yuanyuan Ma, Tao Huang, Xindao Yin, A. Cahid Civelek, Baozhong Shen
KEYWORDS:
18F-Fluoro-2-Deoxyglucose; 18F-Fluorothymidine; 18F-Misonidazole; Microenvironment; Hypoxia; Proliferation
JOURNAL NAME:
International Journal of Medical Physics, Clinical Engineering and Radiation Oncology,
Vol.2 No.1,
February
26,
2013
ABSTRACT:
Positron emission tomography (PET) imaging has emerged
as an important clinical tool for cancer management, and specifically targeted
radiopharmaceuticals play critical roles on PET molecular imaging. Solid
cancers have highly complex and heterogeneous microenvironment, this review
focused on those microenvironmental factors such as hypoxia,
proliferation and perfusion and, accordingly, a novel test system for
validation of current and novel targeted imaging
radiopharmaceuticals. In this review, we have introduced the establishment of
cancer and metastases models in nude mice, visualization of microenvironmental
components of hypoxia, proliferation, perfusion, stroma and necrosis in cancers
and metastases for establishing the microenvironment based model system, and
validation of several radio- pharmaceuticals such as 18F-fluoro-2-deoxyglucose (18F-FDG) 18F-fluorothymidine (18F-FLT), 18F-misonidazole (18F- FMISO) using the
system. We found that 18F-FLT
accumulates in proliferating cancer cells, while 18F-FMISO and 18F-FDG mostly accumulate in hypoxic and
non-proliferative cancer cells, 18F-FDG
shares roughly similar intratumoral distribution pattern with 18F-FMISO and IAZGP, but
mutually excludes 18F-FLT.
This model system validated current tracers for imaging glucose metabolism,
hypoxia and proliferation in cancer and metastases, therefore, can be used for
novel targeted radiopharmaceuticals validation.